Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
An open-label, multiple-dose clinical trial to evaluate the safety/tolerability and pharmacokinetic interaction between DWP14012 and DWC202005 in healthy volunteers
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| DWP14012 Cohort A | Experimental |
| |
| DWP14012 Cohort B | Experimental |
| |
| DWP14012 Cohort C | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| DWC202005, alone | Drug | DWC202005, as a single dose |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Area under the plasma drug concentration-time curve | AUClast of DWC202005 | upto 48 hours postdose |
| Peak Plasma Concentration (Cmax) | Cmax of DWC202005 | upto 48 hours postdose |
| Incidence of Treatment-Emergent Adverse Events | up to 19 days |
Not provided
Not provided
Inclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Nucleus Network (QPharm) | Queensland | Queensland | 78 | Australia |
Not provided
| ID | Term |
|---|---|
| D012847 | Single Person |
| C000634065 | fexuprazan |
| ID | Term |
|---|---|
| D017533 | Marital Status |
| D005191 | Family Characteristics |
| D003710 | Demography |
| D011154 | Population Characteristics |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| DWP14012 + DWC202005 |
| Drug |
DWP14012 and DWC202005, as a single dose |
|
| DWP14012 + DWC202005, after multiple doses of DWP14012 | Drug | DWP14012 and DWC202005, after multiple oral doses of DWP14012 once daily for 12 days |
|
| D012959 |
| Socioeconomic Factors |